Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells

Abstract : To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line. The NLC was prepared by a hot homogenization method and characterized for size, zeta potential, entrapment efficiency (EE) and drug loading (DL). Drug release was evaluated by dialysis in complete DMEM, and NLC aggregation was assayed in the presence of serum. The cytotoxicity of formulations, doxorubicin uptake or penetration were evaluated in MCF-7 and MCF-7/Adr as monolayer or spheroid models.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-02130734
Contributor : Laëtitia Legoupil <>
Submitted on : Thursday, May 16, 2019 - 9:46:38 AM
Last modification on : Thursday, May 16, 2019 - 9:46:38 AM

Identifiers

Citation

Samuel Mussi, Rupa Sawant, Federico Perche, Mônica Oliveira, Ricardo Azevedo, et al.. Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells. Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2014, 31 (8), pp.1882-1892. ⟨10.1007/s11095-013-1290-2⟩. ⟨hal-02130734⟩

Share

Metrics

Record views

5